2cureX announces that patients are successfully being enrolled in the IndiTreat® pancreatic cancer trial
Press Releases Regulatory
2cureX AB (“2cureX”, NASDAQ: 2CUREX), a clinical-stage company that has developed the IndiTreat® test allowing individualization of cancer treatment, hereby announces that the first seven patients have been successfully enrolled into its IndiTreat® pancreatic cancer trial. The trial is conducted at University Hospital Vejle, Denmark.
In November 2018, 2cureX announced that the company, together with its clinical partner University Hospital Vejle, received approval for launching a clinical trial (NCT03821870) in patients with metastatic pancreatic cancer. The first seven patients have been enrolled from March to July 2019. This recruitment rate is on track to finish the enrolment of 30 planned patients in total, in December 2020 as planned.
“Pancreatic cancer is a devastating disease. Too many patients are diagnosed in an advanced stage and we need a breakthrough in the medical treatment. Besides, we are short of tools to predict the efficacy on the individual patient of the drugs we already have. The consequence is that patients often struggle with severe side effects of ineffective treatment”, says Henrik Harling, recently appointed Chief Medical Officer and he continues; “It is our hope that the IndiTreat® test can identify the drug or drug combination that can prolong survival and ensure each patient an acceptable quality of life. The biggest win will be if the test can identify the medical treatment which alone or in combination with radiotherapy may shrink a tumor so much that surgery becomes possible. This scenario will greatly improve the outlook for these patients.”
Pancreatic cancer is the most serious cancer disease with a 5-year survival of 3%. The number of new patients is increasing and it is predicted that the disease will rank as the second leading cause of cancer death within the next ten years. Despite these grim facts only limited new treatment options have found their way to general clinical practice. 2cureX sees a large opportunity in introducing new treatment modalities identified by the IndiTreat® testing.
For more information about 2cureX:
Ole Thastrup, Chief Executive Officer
Telephone: +45 2211 5399
Svensk Kapitalmarknadsgranskning AB
Phone: +46 11 32 30 732
This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on July 23th, 2019.
2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumours that are functionally similar to the patient’s tumour. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.
IndiTreat® is currently being clinically validated in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical studies are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.
The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).